Thymosin alpha-1 vs beta-4: distinct identities and evidence

Thymosin Alpha-1

An immune-modulating peptide studied in T-cell and host-response biology. Research examines immune-cell responses. Outcomes depend on the disease context and the other treatments used. Clinical studies explored specific infectious-disease settings, including chronic hepatitis B. These concern a defined condition and formulation, not a universal improvement in immunity. Immune stimulation is not beneficial in every setting. Transplant-related immunosuppression changes the risk context. This laboratory listing does not inherit the status of prescription formulations used in some countries.

TB-500

A research name associated with thymosin beta-4-related peptides. Thymosin beta-4 participates in actin regulation and cell migration, motivating studies of tissue responses. Some human research concerns pharmaceutical thymosin beta-4 formulations, including ophthalmic products. It does not establish the effects of every material sold as TB-500. A fragment and full-length thymosin beta-4 are not interchangeable. Confirm sequence and molecular identity before applying literature findings. Human safety of the catalogue material is not established.

Comparison limits

A shared category does not prove equal effects, compatibility or suitability. Verify the exact sequence, formulation and batch. Do not substitute a related molecule or ingredient finding for direct evidence.

Compare the catalogue identifiers